Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933666 | 0.90 | TSHR (0.84) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL4338628 | 0.88 | TSHR (0.62) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL10408383 | 0.87 | TSHR (0.66) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL1110552 | 0.87 | TSHR (0.78) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL27908642 | 0.86 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL51316 | 0.86 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL79996 | 0.86 | TSHR (0.63) | TSHRSRCCETPPDPK1MTOR | |
| Hydrochloric Acid SCHEMBL10722992 | 0.84 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL9446520 | 0.84 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL4219700 | 0.84 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982262-B2 | Neutral nucleic acid ligands | VIVONICS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170327826-A1 | NEUTRAL NUCLEIC ACID LIGANDS | VIVONICS, INC. | 2017-11-16 | — | — | US | claimed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-9982262-B2 | Neutral nucleic acid ligands | VIVONICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170327826-A1 | NEUTRAL NUCLEIC ACID LIGANDS | VIVONICS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725724-B2 | Neutral nucleic acid ligands | VIVONICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20140343264-A1 | NEUTRAL NUCLEIC ACID LIGANDS | VIVONICS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-6703376-B2 | ADMINISTERING TO THE AIRWAYS OF THE PATIENT A URIDINE PHOSPHATE SUCH AS URIDINE 5'TRIPHOSPHATE OR DI(URIDINE5') TETRAPHOSPHATE FOR PROMOTING DRAINAGE OF MUCOUS SECRETIONS IN THE CONGESTED AIRWAYS OF A BEDRIDDEN/IMMOBILIZED PATIENT | INSPIRE PHARMACEUTICALS, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020155150-A1 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| CN-1226169-A | Use of uridine triphosphates and related compounds for prevention and treatment of pneumonia in immobilized patients | INSPIRE PHARMACEUTICALS INC (US) | 1999-08-18 | — | — | CN | disclosed |
| US-5763447-A | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS (US) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155150-A1 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | UMPS, UPP1, P2RY1 | TSHR 1457/4885SRC 4446/4885CETP 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.